A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL.

A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL.

Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is in part driven by the tyrosine kinase bcr-abl, but imatinib does not produce long-term remission. Therefore, second-generation ABL inhibitors are currently in clinical investigation. Considering different target specificities...

Full description

Bibliographic Details
Main Authors: Uwe Rix, Jacques Colinge, Katharina Blatt, Manuela Gridling, Lily L Remsing Rix, Katja Parapatics, Sabine Cerny-Reiterer, Thomas R Burkard, Ulrich Jäger, Junia V Melo, Keiryn L Bennett, Peter Valent, Giulio Superti-Furga
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3795025?pdf=render

Internet

http://europepmc.org/articles/PMC3795025?pdf=render

Similar Items